Eikon Therapeutics (NAS: EIKN) key facts
- Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet…
- Eikon Therapeutics (NAS: EIKN)’s last known valuation is $971.7M (Feb 2026).
- It has raised $1.5B; the latest was IPO ($381.2M) in Feb 2026.
- Notable investors include General Catalyst, Lux Capital, Alexandria Venture Investments, StepStone Group, AME Cloud Ventures — 22 tracked in total.
- 1 institutional filer reports fund marks on Eikon Therapeutics (NAS: EIKN) across 2 filings.
- Status: Publicly Held.
Who backs Eikon Therapeutics (NAS: EIKN)
22+- ·The complete investor list: 22 names
- ·Watch Eikon Therapeutics (NAS: EIKN): the Monday email on marks, rounds and moves
Eikon Therapeutics (NAS: EIKN) funding rounds
No funding rounds for Eikon Therapeutics (NAS: EIKN) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Eikon Therapeutics (NAS: EIKN) valuation
Eikon Therapeutics (NAS: EIKN) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $972 million (Feb 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.
Institutional holders and vehicles
1 SEC-registered fund reported 2 fair-value marks on Eikon Therapeutics (NAS: EIKN) between Feb 2026 and May 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Eikon Therapeutics (NAS: EIKN) investors
22 investors are on record for Eikon Therapeutics (NAS: EIKN), including General Catalyst, Lux Capital, Alexandria Venture Investments and StepStone Group. By type, the record holds 7 venture capital firms and 1 family office.
About Eikon Therapeutics (NAS: EIKN)
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
- Sector
- Healthcare
- HQ
- Millbrae, CA, United States
- Founded
- 2019
- Employees
- 384
- Website
- eikontx.com/
- Ownership
- Publicly Held
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Eikon Therapeutics (NAS: EIKN)’s last known valuation, Feb 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.
Institutional fund marks on Eikon Therapeutics (NAS: EIKN)
1 filers · latest May 20261 SEC-registered fund reported 2 fair-value marks on Eikon Therapeutics (NAS: EIKN) between Feb 2026 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View